REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Longevity Base

Longevityadvanced
15
Share
Peptides

2

Avg Daily mcg

0

Level

advanced

Added

May 7, 2026

Overview

The Longevity Base is an advanced peptide protocol targeting two fundamental pillars of biological aging: telomere maintenance and systemic tissue repair. By pairing Epithalon, a synthetic tetrapeptide that activates telomerase, with BPC-157, a gastric pentadecapeptide with extraordinary regenerative properties, this stack addresses aging at both the chromosomal and cellular-functional levels. Epithalon at 10mg administered subcutaneously daily for a 10-day cycle directly stimulates telomerase production in somatic cells. Telomerase is the enzyme responsible for maintaining telomere length, the protective caps on chromosomes that shorten with each cell division and serve as a primary biological clock of aging. Research by Professor Vladimir Khavinson, who pioneered Epithalon development, demonstrated measurable telomere elongation, improved neuroendocrine function, and extended lifespan in animal models. The 10-day intensive protocol followed by extended rest periods (typically 4-6 months between cycles) mirrors the pulsatile approach used in clinical research settings. BPC-157 at 250mcg daily provides continuous systemic repair signaling throughout and beyond the Epithalon cycle. This peptide upregulates growth factor expression (VEGF, EGF, and others), promotes angiogenesis, accelerates wound healing, protects and heals gut lining, and demonstrates neuroprotective properties. Its role in this stack is to maintain tissue integrity and repair capacity while Epithalon works at the deeper chromosomal level. Administer Epithalon subcutaneously in the morning during the 10-day intensive phase. BPC-157 can be taken at any consistent time daily and is continued beyond the Epithalon cycle as a maintenance peptide. This stack is designed for advanced users with established health optimization practices who are focused on long-term biological age reduction. It is particularly suited for those over 40 seeking to slow or partially reverse cellular aging markers. The combination is supported by decades of Russian gerontological research on Epithalon and a growing body of literature on BPC-157 systemic repair mechanisms. Users should monitor biomarkers including telomere length testing, inflammatory markers, and hormonal panels to track progress across cycles.

Dosing Protocol

Epithalon

daily for 10 days· subcutaneous

Read more about Epithalon →

10mg

per dose

BPC-157

Every day· subcutaneous

Read more about BPC-157 →

250mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.